- Home
- ECBK vs LUCD Comparison
ECBK vs LUCD Comparison
Compare ECBK & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | LUCD |
|---|---|---|
| Founded | 1919 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.3M | 182.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECBK | LUCD |
|---|---|---|
| Price | $18.29 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 6.5K | ★ 893.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | 16.67 |
| EPS | ★ 0.38 | N/A |
| Revenue | $598,000.00 | ★ $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | $48.53 | ★ N/A |
| Revenue Growth | 3.64 | ★ 79.00 |
| 52 Week Low | $14.83 | $0.90 |
| 52 Week High | $20.05 | $1.70 |
Technical Indicators
Market Signals| Indicator | ECBK | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 50.29 |
| Support Level | $17.72 | $1.02 |
| Resistance Level | $18.79 | $1.12 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 52.63 | 79.62 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.